DR. DAVID BREWER ANDERSON, DDS
Dentist at Willakenzie Rd, Eugene, OR
License number
Oregon 5852
Category
Dentist
Type
Dentist
Address
Address
2550 Willakenzie Rd, Eugene, OR 97401
Phone
(541) 343-5512
(541) 343-1674 (Fax)
(541) 343-1674 (Fax)
Professional information
Technical Advisor At Dehco
Position:
Northwest Technical advisor/ Warehouse Manager at DEHCO
Location:
Eugene, Oregon Area
Industry:
Wholesale
Work:
DEHCO
since Apr 2000
-
Northwest Technical advisor/ Warehouse Manager
Oregon Icecream
- Eugene, Oregon Area May 1999 - Apr 2000
-
Pasturizer mahine operator CIP
US Marine
- World wide sea to shinny sea Aug 1994 - May 1999
-
CPL
Interests:
4 wheeling, jetski's, diving, Electronics, Having fun.
Dr. David B Anderson, Eugene OR - DDS (Doctor of Dental Surgery)
Specialties:
Dentistry
Address:
2550 Willakenzie Rd, Eugene 97401
(541) 343-5512 (Phone), (541) 343-1674 (Fax)
(541) 343-5512 (Phone), (541) 343-1674 (Fax)
Languages:
English
David Brewer Anderson, Eugene OR
Specialties:
Dentist
Address:
2550 Willakenzie Rd, Eugene, OR 97401
Structurally Biased Random Peptide Libraries Based On Different Scaffolds
US Patent:
2003022, Dec 4, 2003
Filed:
Mar 18, 2003
Appl. No.:
10/393449
Inventors:
David Anderson - Eugene OR, US
Beau Peelle - Cambridge MA, US
Jakob Bogenberger - Ventura CA, US
Beau Peelle - Cambridge MA, US
Jakob Bogenberger - Ventura CA, US
International Classification:
C12Q001/68, C07H021/02, C07H021/04
US Classification:
435/006000, 536/023100
Abstract:
The invention relates to the use of scaffold proteins, particularly green fluorescent protein (GFP), in fusion constructs with random and defined peptides and peptide libraries, to increase the cellular expression levels, decrease the cellular catabolism, increase the conformational stability relative to linear peptides, and to increase the steady state concentrations of the library peptides and peptide library members expressed in cells for the purpose of detecting the presence of the peptides and screening peptide libraries. N-terminal, C-terminal, dual N- and C-terminal and one or more internal fusions are all contemplated. Novel fusions utilizing self-binding peptides to create a conformationally stabilized fusion domain are also contemplated.
Methods Of Identifying Compounds That Modulate Il-4 Receptor-Mediated Ige Synthesis Utilizing A B-Cell Associated Protein
US Patent:
2007013, Jun 14, 2007
Filed:
Feb 20, 2007
Appl. No.:
11/676802
Inventors:
Esteban Masuda - Menlo Park CA, US
Todd Kinsella - Redwood City CA, US
Justin Warner - San Francisco CA, US
Taisei Kinoshita - San Mateo CA, US
Mark Bennett - Moraga CA, US
David Anderson - Eugene OR, US
Todd Kinsella - Redwood City CA, US
Justin Warner - San Francisco CA, US
Taisei Kinoshita - San Mateo CA, US
Mark Bennett - Moraga CA, US
David Anderson - Eugene OR, US
Assignee:
Rigel Pharmaceuticals, Inc. - South San Francisco CA
International Classification:
A61K 38/10, C07K 7/08
US Classification:
514013000, 530326000
Abstract:
The present provides compounds capable of modulating IL-4 receptor-mediated IgE production, as well as IL-4 induced processes associated therewith, methods and kits for identifying such compounds that utilize a BAP-37 as a surrogate analyte and methods of using the compounds in a variety of in vitro, in vitro and ex vivo contexts.
Methods Of Identifying Compounds That Modulate Il-4 Receptor-Mediated Ige Synthesis Utilizing An Adenosine Kinase
US Patent:
2007005, Mar 8, 2007
Filed:
Oct 18, 2006
Appl. No.:
11/550731
Inventors:
Esteban Masuda - Menlo Park CA, US
Todd Kinsella - Redwood City CA, US
Justin Warner - San Francisco CA, US
Taisei Kinoshita - San Mateo CA, US
Mark Bennett - Moraga CA, US
David Anderson - Eugene OR, US
Todd Kinsella - Redwood City CA, US
Justin Warner - San Francisco CA, US
Taisei Kinoshita - San Mateo CA, US
Mark Bennett - Moraga CA, US
David Anderson - Eugene OR, US
Assignee:
Rigel Pharmaceuticals, Inc. - South San Francisco CA
International Classification:
C07K 14/47, A61K 38/16
US Classification:
514013000, 530325000
Abstract:
The present provides compounds capable of modulating IL-4 receptor-mediated IgE production, as well as IL-4 induced processes associated therewith, methods and kits for identifying such compounds that utilize an adenosine kinase as a surrogate analyte and methods of using the compounds in a variety of in vitro, in vitro and ex vivo contexts.